The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $128.9 in the prior trading day, Abbott Laboratories (NYSE: ABT) closed at $128.01, down -0.69%. In other words, the price has decreased by -$0.69 from its previous closing price. On the day, 5.77 million shares were traded. ABT stock price reached its highest trading level at $129.85 during the session, while it also had its lowest trading level at $127.96.
Ratios:
Our goal is to gain a better understanding of ABT by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 28.78 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 32.18. For the most recent quarter (mrq), Quick Ratio is recorded 1.24 and its Current Ratio is at 1.70. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.23.
Upgrades & Downgrades
In the most recent recommendation for this company, The Benchmark Company on October 10, 2025, initiated with a Buy rating and assigned the stock a target price of $145.
On July 18, 2025, Jefferies Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $145. On June 16, 2025, Leerink Partners started tracking the stock assigning a Market Perform rating and target price of $143.Leerink Partners initiated its Market Perform rating on June 16, 2025, with a $143 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 25 ’25 when Shroff Eric sold 1,586 shares for $128.02 per share. The transaction valued at 203,043 led to the insider holds 30,384 shares of the business.
Eric Shroff bought 1,586 shares of ABT for $203,042 on Nov 25 ’25. On Aug 08 ’25, another insider, Boudreau Philip P, who serves as the EVP AND CFO of the company, sold 5,550 shares for $134.55 each. As a result, the insider received 746,758 and left with 51,003 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABT now has a Market Capitalization of 222796152832 and an Enterprise Value of 228145004544. As of this moment, Abbott’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.06, and their Forward P/E ratio for the next fiscal year is 22.59. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.56. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.08 while its Price-to-Book (P/B) ratio in mrq is 4.37. Its current Enterprise Value per Revenue stands at 5.204 whereas that against EBITDA is 19.422.
Stock Price History:
The Beta on a monthly basis for ABT is 0.71, which has changed by 0.10078251 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, ABT has reached a high of $141.23, while it has fallen to a 52-week low of $110.86. The 50-Day Moving Average of the stock is -1.06%, while the 200-Day Moving Average is calculated to be -2.29%.
Shares Statistics:
The stock has traded on average 6.17M shares per day over the past 3-months and 7983260 shares per day over the last 10 days, according to various share statistics. A total of 1.74B shares are outstanding, with a floating share count of 1.73B. Insiders hold about 0.67% of the company’s shares, while institutions hold 80.55% stake in the company. Shares short for ABT as of 1763078400 were 19141411 with a Short Ratio of 3.10, compared to 1760486400 on 19360135. Therefore, it implies a Short% of Shares Outstanding of 19141411 and a Short% of Float of 1.11.
Dividends & Splits
In the trailing 12 months, ABT’s forward annual dividend rate was 2.36, compared to 2.36 this year. Against a Trailing Annual Dividend Yield of 0.018308766. The stock’s 5-year Average Dividend Yield is 1.72. The current Payout Ratio is 29.33% for ABT, which recently paid a dividend on 2025-10-15 with an ex-dividend date of 2025-10-15. Stock splits for the company last occurred on 2013-01-02 when the company split stock in a 10000:4798 ratio.
Earnings Estimates
The market rating for Abbott Laboratories (ABT) is a result of the insights provided by 24.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $1.2, with high estimates of $1.3 and low estimates of $1.14.
Analysts are recommending an EPS of between $5.2 and $5.14 for the fiscal current year, implying an average EPS of $5.15. EPS for the following year is $5.68, with 28.0 analysts recommending between $5.85 and $5.51.
Revenue Estimates
24 analysts predict $11.8B in revenue for. The current quarter. It ranges from a high estimate of $11.87B to a low estimate of $11.71B. As of. The current estimate, Abbott Laboratories’s year-ago sales were $10.97BFor the next quarter, 24 analysts are estimating revenue of $11.19B. There is a high estimate of $11.52B for the next quarter, whereas the lowest estimate is $10.92B.
A total of 28 analysts have provided revenue estimates for ABT’s current fiscal year. The highest revenue estimate was $44.84B, while the lowest revenue estimate was $44.58B, resulting in an average revenue estimate of $44.67B. In the same quarter a year ago, actual revenue was $41.95BBased on 28 analysts’ estimates, the company’s revenue will be $48.22B in the next fiscal year. The high estimate is $50.47B and the low estimate is $47.11B.
